The cardioprotective potential of selected species of mistletoe

Mistletoe is an evergreen woody shrub with stems measuring 30-100 cm. It has leathery, yellowish-green strap-shaped leaves, yellowish-green flowers, and bears typical berries. The most common species is Viscum album L., mainly present in Europe and Asia. It is commonly known as European mistletoe or...

Full description

Saved in:
Bibliographic Details
Main Author: Beata Olas (Author)
Format: Book
Published: Frontiers Media S.A., 2024-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_02fbbfbf49434e0ab9862851db7cad6b
042 |a dc 
100 1 0 |a Beata Olas  |e author 
245 0 0 |a The cardioprotective potential of selected species of mistletoe 
260 |b Frontiers Media S.A.,   |c 2024-04-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2024.1395658 
520 |a Mistletoe is an evergreen woody shrub with stems measuring 30-100 cm. It has leathery, yellowish-green strap-shaped leaves, yellowish-green flowers, and bears typical berries. The most common species is Viscum album L., mainly present in Europe and Asia. It is commonly known as European mistletoe or simply, mistletoe. Scientific interest in mistletoe was awakened in the XX century. Mistletoe, especially V. album L., has historically been used in the treatment and prophylaxis of CVD, with its properties being confirmed in recent studies. This mini-review describes new aspects of the cardioprotective properties of various species of mistletoe, especially V. album L. The effect of oral and subcutaneous application of fresh V. album L. extracts on blood pressure has been studied in various models; while the data suggests that mistletoe may be a promising herbal extract with cardioprotective properties, the species has only been tested in vitro and in vivo, on animals. In addition, it is unclear whether the cardioprotective activity of mistletoe may be due to particular chemical components, as the chemical composition of mistletoe extracts can vary depending on inter alia the time of harvest, extraction method and plant part. Hence, this activity may instead result from synergistic interactions between various secondary metabolites. Therefore, further studies are needed to identify the mechanisms of action of mistletoe compounds on CVDs, and determine their interactions with other cardioprotective drugs, their metabolic mechanisms, pharamacokinetics and adverse effects. More research is also needed to determine the therapeutic doses of active ingredients for use in clinical trials; this would require an accurate understanding of the chemical composition of extracts from different species of mistletoe (not only V. album L.) and from various host trees. 
546 |a EN 
690 |a cardiovascular disease 
690 |a cardiovascular activity 
690 |a hypertension 
690 |a mistletoe 
690 |a viscotoxin 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 15 (2024) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fphar.2024.1395658/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/02fbbfbf49434e0ab9862851db7cad6b  |z Connect to this object online.